Friday, July 28, 2023
Prometheus Laboratories Inc., a leading precision healthcare company, has announced the introduction of PredictrPK ADA, a precision-guided dosing test tailored for adult Crohn's disease (CD) patients undergoing ADA treatment. With this launch, Prometheus has successfully developed and commercialized precision-guided dosing tests for two widely used biologics in inflammatory bowel disease (IBD), ADA and infliximab. This testing platform marks a significant milestone in precision medicine for immune-mediated conditions, offering personalized care and optimizing treatment outcomes.
PredictrPK tests address the considerable variability in initial therapeutic responses among patients and support the persistence of biologic therapies. By analyzing a patient's unique pharmacokinetic and clearance profile, healthcare providers can make informed decisions about adjusting biologic treatments. This includes tapering dosages during remission, escalating dosages when a loss of response is suspected, and making therapeutic switches to achieve better responses. The ultimate goal is to maximize therapeutic effectiveness while minimizing disease flares and reducing unnecessary healthcare costs.
Dr. Bincy Abraham, IBD Specialist at Houston Methodist Weill-Cornell Department of Medicine, emphasizes the transformative impact of individualized, actionable data on patient care. Access to precision-guided dosing eliminates guesswork, allowing IBD providers to predict drug levels accurately and adjust dosages more effectively.
At the Digestive Disease Week® (DDW®) 2023 Congress, Prometheus collaborated on six presentations that explored the relationship between patient pharmacokinetics and treatment outcomes. Among various factors studied, drug clearance emerged as significantly associated with disease control in CD. Two separate studies revealed that ADA clearance below identified thresholds correlated with a 4- to 5-fold increased likelihood of endoscopic remission (Wright et al), while accelerated ADA clearance was linked to a lack of CD disease control (McGovern et al). These findings may help stratify patients who could benefit from early dose optimization.
Thierry Dervieux, Chief Scientific Officer at Prometheus and co-investigator on the DDW studies, highlights the significance of incorporating calculated ADA clearance as a top-line result in PredictrPK ADA. For over two decades, Prometheus has been advancing patient care with innovative testing services, driven by an understanding of current and future unmet needs. The combination of individualized ADA dosing guidance and clearance information in PredictrPK ADA represents a major step forward in biologic management, offering enhanced precision and patient outcomes.